Institute for International Research

This page will be used to provide paid delegates of the conference with access to any presentations that were not included in the conference documentation. Only paid conference delegates have permission to access IIR online documentation.

While these presentations were not available to be included in your conference documentation, IIR is pleased to make them available to all conference delegates through this web site.

You will need the freely available Adobe Acrobat Reader, which is available by clicking here. To access the presentations:

• Click the title of the session
  
• You can choose to view the file online or save the file to your computer
  
• You can print the files and add them to your other conference materials

Current Therapeutic Issues Follow On Protein Products
Robert Bell, Ph.D.
Drug & Biotechnology Development, LLC

Generic Pharma's Race to Merge and Acquire:
Critical Issues to Consider when Entering into an M&A Transaction
Panel Discussion

Update on FTC Pharma Actions
Markus H. Meier, Assistant Director
Federal Trade Commission

FOPPs, Biological Generics, and Biosimilars
A US and EU Regulatory Update
Suzanne M. Sensabaugh, MS, MBA VP, Biopharmaceutical Development
MDS Pharma

September 28, 2006
State Antitrust Enforcement in the
Pharmaceutical Industry
Meredyth Smith Andrus,
Federal Trade Commission

"Authorized Generics"
Windfall to consumers or new strategy to harm competition?
David A. Balto

US Trends, Issues, Outlook
Strategic Management Review 2006
Diana Conmy, Corporate Director, Market Insights
IMS HEALTH

Predicting the Next Wave:
Changes in the Global Generic Sector Implications for Manufacturers & Investors
Jean Hoffman, President
Q Street Advisors, Inc.

Wall Street View of the Generic Industry -
The Challenges & Opportunities
Richard B. Silver, Senior Vice President, Specialty Pharmaceuticals Research
Lehman Brothers

Defending Against Preliminary Injunctions and Temporary Restraining Orders
Charles A. Weiss
Kenyon & Kenyon LLP

505(b)(2) NDA's: Risks and Rewards of Generic Innovation
Vickie O'Neill, Vice President, Research and Technology Development
Upsher-Smith

Inequitable Conduct – Practicing Fraud In Pharmaceutical and Biotech Patent Law
Shashank Upadhye, Esq. Vice President Head of Intellectual Property & Regulatory
Sandoz U.S.

Follow-on Biologics – Will They Be Different Economically From Generics?
Henry Grabowski
Duke University